Cross Linking News and Research

RSS

Research findings may lead to new ways to thwart drug resistance

Penicillin, the wonder drug discovered in 1928, works in ways that are still mysterious almost a century later. One of the oldest and most widely used antibiotics, it attacks enzymes that build the bacterial cell wall, a mesh that surrounds the bacterial membrane and gives the cells their integrity and shape. Once that wall is breached, bacteria die -- allowing us to recover from infection.

6 Dec 2014

Lab-grown tissues may provide new treatments for injuries, damage to the joints

Lab-grown tissues could one day provide new treatments for injuries and damage to the joints, including articular cartilage, tendons and ligaments.

31 Oct 2014

Study: New blood substitute may be safer than donor blood

A new blood substitute has been developed which could be a safer and more effective alternative to using donor blood.

29 Oct 2014

New hydrogel instantly turns from liquid to semisolid at close to body temperature

Rice University bioengineers have created a hydrogel that instantly turns from liquid to semisolid at close to body temperature - and then degrades at precisely the right pace.

8 May 2014

French researchers introduce new method to effectively control bleeding and repair tissues

Stopping bleeding, closing wounds, repairing organs—these are everyday challenges in medical and surgical practice. In the journal Angewandte Chemie, French researchers have now introduced a new method that employs gluing by aqueous nanoparticle solutions to effectively control bleeding and repair tissues. In animal tests, their approach proved easy to apply, rapid and efficient even in situations when conventional methods are traumatic or fail.

25 Apr 2014

Avedro receives Canadian approval for KXL II System

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today the Canadian approval for the company's KXL II System. The KXL II System performs a procedure called PiXL (Photorefractive Intrastromal Cross-Linking) which has the potential to deliver non-surgical correction of myopia, and improve cataract surgery outcomes.

23 Apr 2014

Research provides fresh insight into structure of sodium channels

Sodium channels are implicated in many serious conditions such as heart disease, epilepsy and pain, making them an important potential target for drug therapies. Unfortunately, there is still much scientists do not know about the molecules.

18 Apr 2014

$Meta-analysis study shows association between BTMs s-CTX, s-PINP and risk of future fractures$

Meta-analysis study shows association between BTMs s-CTX, s-PINP and risk of future fractures

A new study by an International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) scientific working group summarizes the clinical performance of serum procollagen type I N propeptide (s-PINP) and serum C-terminal cross-linking telopeptide of type I collagen (s-CTX) in fracture risk prediction in untreated individuals in prospective cohort studies.

5 Mar 2014

Abingworth announces final closing of £225M ($375M) fund

Abingworth, the international investment group dedicated to life sciences and healthcare, today announced the final closing of its £225m ($375m) fund, Abingworth Bioventures VI (ABV VI). ABV VI, Abingworth's 10th life sciences fund, exceeded its target of £200 million and invests in life sciences and healthcare both in Europe and the US.

28 Feb 2014

Rice U. develops temperature-sensitive gelling scaffolds to regenerate craniofacial bone

Rice University bioengineers have developed a hydrogel scaffold for craniofacial bone tissue regeneration that starts as a liquid, solidifies into a gel in the body and liquefies again for removal.

12 Dec 2013

FDA grants priority review status to Avedro's riboflavin ophthalmic solution/KXL system

Avedro Inc, a Boston-based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date at March 15th, 2014.

25 Nov 2013

Avedro initiates US clinical trials for Lasik with cross-linking and pulsed accelerated cross-linking

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces today that the first patients have been treated in two new US clinical trials: Lasik with Cross-linking and Pulsed Accelerated Cross-linking.

12 Nov 2013

Avedro gets CE Mark clearance for KXL II System

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces CE Mark clearance for its KXL II System. The KXL II System has the potential for non-surgical correction of myopia, as well as improving cataract surgery outcomes, with a procedure called PiXL (Photorefractive Intrastromal Cross-linking).

5 Nov 2013

Research findings open up possibility for developing potent anti-clotting drugs

Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing. By blocking this switch in lab mice, the researchers prevented small clots from growing -- a process that can pose a danger in humans -- while preserving their ability to staunch bleeding

29 Oct 2013

Modern strains of MRSA have become broadly resistant to antibiotics: Study

University of Notre Dame researchers Shahriar Mobashery and Mayland Chang and their collaborators in Spain have published research results this week that show how methicillin-resistant Staphylococcus aureus (MRSA) regulates the critical crosslinking of its cell wall in the face of beta-lactam antibiotics.

5 Oct 2013

New reagent kits for intracellular staining from Beckman Coulter Life Sciences

PerFix-Expose1 and PerFix-nc1, innovative new reagent kits for intracellular staining from Beckman Coulter Life Sciences, minimize sample manipulation for a streamlined workflow that delivers high quality results. Developed for use on Beckman Coulter’s Gallios1 and Navios2 series flow cytometers and compatible with all Beckman Coulter Life Sciences’ fluorochromes, the kits enable a clear focus on the cytoplasmic and nuclear compartments of the cell.

8 Aug 2013